PF-Atlas › Mechanisms › Dual integrin inhibitor — blocks TGF-β activation at source via αvβ6/αvβ1
Dual integrin inhibitor — blocks TGF-β activation at source via αvβ6/αvβ1 in IPF
Mechanism of action · idiopathic pulmonary fibrosis
Overview
Dual integrin inhibitor — blocks TGF-β activation at source via αvβ6/αvβ1 is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 1 drug and 0 clinical trials acting through this mechanism.
Drugs targeting Dual integrin inhibitor — blocks TGF-β activation at source via αvβ6/αvβ1
Therapies
Medical disclaimer. This is a research summary, not medical advice.